Schading, Simon
Pohl, Heiko
Gantenbein, Andreas
Luechinger, Roger
Sandor, Peter
Riederer, Franz
Freund, Patrick
Michels, Lars
Funding for this research was provided by:
Werner Dessauer Foundation
Article History
Received: 8 September 2021
Accepted: 27 October 2021
First Online: 20 November 2021
Declarations
:
: Stated in Participants and Exclusion/Inclusion criteria section of Methods: <i>“All participants gave their informed consent and the study was approved by the local ethics committee.”</i>
: Not applicable.
: Pohl received speaker fees from TEVA Pharmaceuticals and honoraria from Eli Lilly. Franz Riederer has received speaker honoraria from Burgerstein Foundation, Lilly, Teva, and Novartis. Dr. Sandor reports personal fees from Novartis, Teva, Lilly, Almirall, outside the submitted work. Simon Schading, Dr. Gantenbein, Dr. Luechinger, Dr. Freund, and Dr. Michels have no conflicts of interest to disclose.